Imeglimin-based therapies improve glycemic control and reduce mitochondrial stress in type 2 diabetes: a prospective cohort study.

Front Endocrinol (Lausanne) · 2025 · PMC12500445 · PMID 41064360

Europe PMC DOI

hedged sentences

0.0530

closest p · 1.1× alpha

0.1310

boldest claim

The sentences

showed a trendp=0.053so close (0.05 < p ≤ 0.1)

Notably, Imeglimin + Metformin showed a trend toward HbA1c reduction versus control (p=0.053), while Imeglimin monotherapy did not differ significantly from control.

also in 53,322 other papers

did not reach statistical significancep=0.131not close (p > 0.1)

Of note, although Δ serum NLRP3 had moderate correlations with Δ IL-6 (r=0.41) and Δ IL-18 (r=0.37), these did not reach statistical significance (p=0.131 and 0.14, respectively). 3.3 Within group comparisons of changes in ccf-mtDNA and inflammatory markers The paired t-test analysis highlights that combination therapies, especially Imeglimin + other OHA and Metformin + other OHA, produced significant reductions in key metabolic and inflammatory parameters.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.